CytomX Therapeutics Shares Outstanding History (CTMX)
CytomX Therapeutics reported 170.2M shares outstanding at the end of fiscal 2025.
View full CytomX Therapeutics company overviewCytomX Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 170.2M | 90.1M | +112.47% |
| 2024 | 2024-12-31 | 80.1M | 12.8M | +19.00% |
| 2023 | 2023-12-31 | 67.3M | 1.1M | +1.63% |
| 2022 | 2022-12-31 | 66.2M | 835,288 | +1.28% |
| 2021 | 2021-12-31 | 65.4M | 17.1M | +35.52% |
| 2020 | 2020-12-31 | 48.3M | 2.7M | +5.99% |
| 2019 | 2019-12-31 | 45.5M | 439,879 | +0.98% |
| 2018 | 2018-12-31 | 45.1M | 6.6M | +17.16% |
| 2017 | 2017-12-31 | 38.5M | 2.0M | +5.45% |
| 2016 | 2016-12-31 | 36.5M | 456,960 | +1.27% |
| 2015 · Dec 31 | 2015-12-31 | 36.0M | 0 | 0.00% |
| 2015 · Dec 10 | 2015-12-10 | 36.0M | 35.0M | +3515.90% |
| 2014 | 2014-12-31 | 996,520 | — | — |
CytomX Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 170.2M | 104.2M | +158.05% |
| Q4 2024 | 2024-12-31 | 80.1M | 14.3M | +21.81% |
| Q4 2023 | 2023-12-31 | 67.3M | 1.9M | +2.92% |
| Q4 2022 | 2022-12-31 | 66.2M | 835,288 | +1.28% |
| Q3 2022 | 2022-09-30 | 66.0M | 701,126 | +1.07% |
| Q2 2022 | 2022-06-30 | 65.8M | 599,489 | +0.92% |
| Q1 2022 | 2022-03-31 | 65.4M | 395,458 | +0.61% |
| Q4 2021 | 2021-12-31 | 65.4M | 17.1M | +35.52% |
| Q3 2021 | 2021-09-30 | 65.2M | 19.0M | +41.16% |
| Q2 2021 | 2021-06-30 | 65.2M | 19.0M | +41.06% |
| Q1 2021 | 2021-03-31 | 65.0M | 19.1M | +41.56% |
| Q4 2020 | 2020-12-31 | 48.3M | 2.7M | +5.99% |
| Q3 2020 | 2020-09-30 | 46.2M | 796,934 | +1.75% |
| Q2 2020 | 2020-06-30 | 46.2M | 786,232 | +1.73% |
| Q1 2020 | 2020-03-31 | 45.9M | 760,964 | +1.69% |
| Q4 2019 | 2019-12-31 | 45.5M | 439,879 | +0.98% |
| Q3 2019 | 2019-09-30 | 45.4M | 429,189 | +0.95% |
| Q2 2019 | 2019-06-30 | 45.4M | 6.4M | +16.38% |
| Q1 2019 | 2019-03-31 | 45.2M | 6.3M | +16.08% |
| Q4 2018 | 2018-12-31 | 45.1M | 6.6M | +17.16% |
| Q3 2018 | 2018-09-30 | 45.0M | 7.9M | +21.30% |
| Q2 2018 | 2018-06-30 | 39.0M | 2.2M | +5.90% |
| Q1 2018 | 2018-03-31 | 38.9M | 2.2M | +5.95% |
| Q4 2017 | 2017-12-31 | 38.5M | 2.0M | +5.45% |
| Q3 2017 | 2017-09-30 | 37.1M | 702,641 | +1.93% |
| Q2 2017 | 2017-06-30 | 36.8M | 651,997 | +1.80% |
| Q1 2017 | 2017-03-31 | 36.7M | 633,131 | +1.75% |
| Q4 2016 | 2016-12-31 | 36.5M | 456,960 | +1.27% |
| Q3 2016 | 2016-09-30 | 36.4M | 359,612 | +1.00% |
| Q2 2016 | 2016-06-30 | 36.2M | 36.2M | +208207.50% |
| Q1 2016 | 2016-03-31 | 36.1M | 35.1M | +3521.18% |
| Q4 2015 | 2015-12-31 | 36.0M | — | — |
| Q4 2015 | 2015-12-10 | 36.0M | — | — |
| Q3 2015 | 2015-09-30 | 17,372.08 | — | — |
| Q4 2014 | 2014-12-31 | 996,520 | — | — |
CytomX Therapeutics shares outstanding trends
Over the last five reported fiscal years, CytomX Therapeutics's shares outstanding moved from 48.3M to 170.2M, a change of 121.9M. The latest reported quarter, Q4 2025, shows 170.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CytomX Therapeutics filings at SEC.gov ↗